Allogene Therapeutics, Inc.

NasdaqGS:ALLO 株式レポート

時価総額：US$465.6m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Allogene Therapeutics マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

David Chang

最高経営責任者

US$14.1m

報酬総額

CEO給与比率5.1%
CEO在任期間6yrs
CEOの所有権3.7%
経営陣の平均在職期間1.3yrs
取締役会の平均在任期間6.2yrs

経営陣の近況

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

Recent updates

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Jun 12

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside

Apr 01

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Jun 09
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Feb 22
We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Oct 27
Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate

Oct 06

An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued

Sep 22
An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued

Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A

Sep 13

Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M

Aug 09

Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

Jul 14
Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

Allogene Therapeutics: Multibagger Potential, But Terribly Risky

Jun 24

Allogene: Leading The Allogeneic CAR-T Space, Again

Apr 01

Allogene: Lifting Of The Clinical Hold Will Be A Major Binary

Jan 12

CEO報酬分析

Allogene Therapeutics の収益と比較して、David Chang の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$292m

Dec 31 2023US$14mUS$724k

-US$327m

Sep 30 2023n/an/a

-US$342m

Jun 30 2023n/an/a

-US$364m

Mar 31 2023n/an/a

-US$361m

Dec 31 2022US$15mUS$724k

-US$340m

Sep 30 2022n/an/a

-US$313m

Jun 30 2022n/an/a

-US$308m

Mar 31 2022n/an/a

-US$304m

Dec 31 2021US$10mUS$695k

-US$182m

Sep 30 2021n/an/a

-US$251m

Jun 30 2021n/an/a

-US$239m

Mar 31 2021n/an/a

-US$229m

Dec 31 2020US$8mUS$675k

-US$316m

Sep 30 2020n/an/a

-US$243m

Jun 30 2020n/an/a

-US$227m

Mar 31 2020n/an/a

-US$207m

Dec 31 2019US$11mUS$600k

-US$185m

Sep 30 2019n/an/a

-US$154m

Jun 30 2019n/an/a

-US$147m

Mar 31 2019n/an/a

-US$240m

Dec 31 2018US$13mUS$362k

-US$212m

報酬と市場: Davidの 総報酬 ($USD 14.06M ) は、 US市場 ($USD 2.44M ) の同規模の企業の平均を上回っています。

報酬と収益: Davidの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

David Chang (64 yo)

6yrs

在職期間

US$14,061,848

報酬

Dr. David D. Chang, M.D., Ph.D. is the President, Chief Executive Officer and Director of Allogene Therapeutics, Inc since June 2018. He served as Chief Medical Officer and Executive Vice President of Rese...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Arie Belldegrun
Co-Founder & Executive Chairman6.6yrsUS$9.36m2.94%
$ 13.7m
David Chang
Co-Founder6yrsUS$14.06m3.7%
$ 17.2m
Joshua Kazam
Co-Founder & Directorno dataUS$684.49k0.15%
$ 675.8k
Timothy Moore
Executive VP & Chief Technical Officer1.2yrsUS$5.80m0.13%
$ 592.0k
Zachary Roberts
Executive VP of Research & Development and Chief Medical Officer1.4yrsUS$8.13m0.018%
$ 85.4k
Geoffrey Parker
Executive VP & CFOless than a yearデータなし0.17%
$ 769.4k
Annie Yoshiyama
Senior VPno dataデータなしデータなし
Earl Douglas
Senior VPless than a yearデータなし0%
$ 0
Susan Lundeen
Chief People Officer2.1yrsデータなしデータなし
Christine Cassiano
Executive VP1.4yrsデータなしデータなし
Yinlin Chen
Senior Vice President of Financeno dataデータなし0.043%
$ 198.2k
David Tanen
Secretaryno dataデータなしデータなし

1.3yrs

平均在職期間

58.5yo

平均年齢

経験豊富な経営陣: ALLOの経営陣は 経験豊富 とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Arie Belldegrun
Co-Founder & Executive Chairman6.6yrsUS$9.36m2.94%
$ 13.7m
David Chang
Co-Founder6yrsUS$14.06m3.7%
$ 17.2m
Joshua Kazam
Co-Founder & Director6.6yrsUS$684.49k0.15%
$ 675.8k
David Bonderman
Lead Independent Director6.2yrsデータなしデータなし
Franz Humer
Independent Director6.2yrsUS$585.00k0.15%
$ 706.3k
Owen Witte
Independent Director6.2yrsUS$510.00k0.12%
$ 569.9k
Todd Sisitsky
Independent Director6.2yrsデータなしデータなし
Deborah Messemer
Independent Director5.8yrsUS$495.00k0.089%
$ 413.4k
Matthew Porteus
Member of Scientific Advisory Boardno dataデータなしデータなし
Donald Kohn
Member of Scientific Advisory Boardno dataデータなしデータなし
Antonius Schumacher
Chairman of Scientific Advisory Boardno dataデータなしデータなし
John DeYoung
Independent Director6.2yrsデータなしデータなし

6.2yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: ALLOの 取締役会 は 経験豊富 であると考えられます ( 6.2年の平均在任期間)。